Enveric Biosciences Reports Exit/Disposal Costs
Ticker: ENVB · Form: 8-K · Filed: Jan 8, 2024 · CIK: 890821
| Field | Detail |
|---|---|
| Company | Enveric Biosciences, Inc. (ENVB) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01, $40,000 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: restructuring, operational-change, disposal-activities
TL;DR
**Enveric Biosciences is reporting costs tied to exiting or disposing of activities, signaling potential operational changes.**
AI Summary
Enveric Biosciences, Inc. filed an 8-K on January 8, 2024, reporting 'Cost Associated with Exit or Disposal Activities.' This filing indicates that the company is undergoing some form of restructuring or winding down certain operations, which could involve significant costs. For investors, this matters because such activities often signal a shift in strategy, potential asset sales, or even a reduction in workforce, all of which can impact future profitability and stock valuation.
Why It Matters
This filing signals potential restructuring or winding down of operations, which could impact Enveric Biosciences' financial health and future strategic direction.
Risk Assessment
Risk Level: medium — The 'Cost Associated with Exit or Disposal Activities' can indicate significant operational changes or financial strain, introducing uncertainty for investors.
Analyst Insight
An investor should monitor subsequent filings for details on the nature and magnitude of these 'exit or disposal activities' to assess their impact on Enveric Biosciences' financial outlook and strategic direction.
Key Players & Entities
- Enveric Biosciences, Inc. (company) — the registrant filing the 8-K
- 001-38286 (null) — Commission File Number for Enveric Biosciences, Inc.
- 95-4484725 (null) — I.R.S. Employer Identification No. for Enveric Biosciences, Inc.
- Delaware (null) — State of incorporation for Enveric Biosciences, Inc.
- January 8, 2024 (null) — Date of Report (Date of earliest event reported)
- ENVB (null) — Trading Symbol for Enveric Biosciences, Inc.
- The Nasdaq Stock Market (null) — Exchange where Enveric Biosciences, Inc. common stock is registered
FAQ
What is the primary event reported in this 8-K filing by Enveric Biosciences, Inc.?
The primary event reported in this 8-K filing by Enveric Biosciences, Inc. is 'Cost Associated with Exit or Disposal Activities' as per the 'ITEM INFORMATION' section.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 8, 2024, as stated under 'Date of Report (Date of earliest event reported)'.
What is the trading symbol and the exchange where Enveric Biosciences, Inc.'s common stock is registered?
Enveric Biosciences, Inc.'s common stock trades under the symbol ENVB and is registered on The Nasdaq Stock Market, as indicated in the 'Securities registered pursuant to Section 12(b) of the Act' section.
What is the business address and phone number of Enveric Biosciences, Inc.?
The business address for Enveric Biosciences, Inc. is 4851 Tamiami Trail N, Suite 200, Naples, FL 34103, and their telephone number is (239) 302-1707, as listed in the 'BUSINESS ADDRESS' section.
What was the former name of Enveric Biosciences, Inc. and when did the name change occur?
Enveric Biosciences, Inc. was formerly known as AMERI Holdings, Inc., with a name change date of 20150527, and even before that, SPATIALIZER AUDIO LABORATORIES INC, with a name change date of 19950323, as detailed in the 'FORMER COMPANY' section of the filing.
Filing Stats: 949 words · 4 min read · ~3 pages · Grade level 15.8 · Accepted 2024-01-08 16:42:54
Key Financial Figures
- $0.01 — ch registered Common stock, par value $0.01 per share ENVB The Nasdaq Stock Mar
- $40,000 — y estimates it will incur approximately $40,000 of costs, consisting primarily of cash
Filing Documents
- form8-k.htm (8-K) — 37KB
- 0001493152-24-001717.txt ( ) — 209KB
- envb-20240108.xsd (EX-101.SCH) — 3KB
- envb-20240108_lab.xml (EX-101.LAB) — 33KB
- envb-20240108_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 8, 2024 ENVERIC BIOSCIENCES, INC. By: /s/ Joseph Tucker Joseph Tucker Chief Executive Officer